Drug Type Recombinant protein |
Synonyms OHB 101, OHB101, TAK-752 + [1] |
Target |
Mechanism CD32B antagonists(Low affinity immunoglobulin gamma Fc region receptor II-b antagonists) |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Purpura, Thrombocytopenic, Idiopathic | Phase 2 | US | 07 Feb 2022 | |
Systemic Lupus Erythematosus | Phase 2 | US | 07 Feb 2022 |